Want to see SE:ACOU full AI Analyst Report?
Top Page
AcouSort AB
(ACOU)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr2.50
▼(-16.39% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by heavy operating losses, negative gross profit, and ongoing negative free cash flow alongside shrinking equity. Technicals also remain bearish with the stock below key moving averages and negative MACD, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
No reported debt materially reduces solvency and interest-burden risk, giving AcouSort greater flexibility while it develops its commercial business. This conservative financing profile can help the company preserve strategic options during periods of uneven profitability and cash generation.
Negative Factors
Deep operating losses
Negative gross profit and substantial operating and net losses show that AcouSort has not yet established a stable, scalable profit model. Even with losses narrowing versus earlier periods, deeply negative margins can constrain reinvestment and require continued improvement in commercial execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt materially reduces solvency and interest-burden risk, giving AcouSort greater flexibility while it develops its commercial business. This conservative financing profile can help the company preserve strategic options during periods of uneven profitability and cash generation.
Read all positive factors
AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr52.91M
Dividend YieldN/A
Average Volume (3M)27.90K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth43.22%
EPS Growth36.11%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.52
Shares Outstanding21,163,902
10 Day Avg. Volume26,161
30 Day Avg. Volume27,903
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.40M
AcouSort AB Business Overview & Revenue Model
Company Description
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellula...
How the Company Makes Money
AcouSort AB makes money primarily by commercializing its acoustofluidic separation technology to customers who need to integrate cell/particle separation and washing into their instruments or manufacturing workflows. Key revenue streams include: (...
AcouSort AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.97M | 6.85M | 4.74M | 10.55M | 4.96M | 3.01M |
| Gross Profit | -7.90M | -14.50M | 4.77M | 8.39M | 2.91M | 548.00K |
| EBITDA | -12.17M | -14.33M | -15.89M | -16.70M | -12.86M | -11.46M |
| Net Income | -11.22M | -12.15M | -15.08M | -17.09M | -13.21M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 21.47M | 17.89M | 12.32M | 34.51M | 42.66M | 36.56M |
| Cash, Cash Equivalents and Short-Term Investments | 9.48M | 6.29M | 3.57M | 23.99M | 33.97M | 31.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.67M | 1.59M | 3.86M | 10.38M | 22.54M | 3.54M |
| Stockholders Equity | 9.81M | 16.30M | 8.46M | 24.14M | 20.11M | 33.02M |
Cash Flow | ||||||
| Free Cash Flow | -6.91M | -17.27M | -19.84M | -31.77M | 2.95M | -12.23M |
| Operating Cash Flow | -6.58M | -16.78M | -18.81M | -31.56M | 3.96M | -10.92M |
| Investing Cash Flow | -1.39M | -488.00K | -1.02M | -1.16M | -1.01M | -1.31M |
| Financing Cash Flow | -118.00K | 18.98M | -157.00K | 22.08M | 0.00 | 35.63M |
AcouSort AB Technical Analysis
Negative
2.99
Price Trends
3.09
Negative
3.63
Negative
3.26
Negative
Market Momentum
-0.13
Positive
31.93
Neutral
6.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.99 is above the 20-day moving average (MA) of 2.80, below the 50-day MA of 3.09, and below the 200-day MA of 3.26, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 31.93 is Neutral, neither overbought nor oversold. The STOCH value of 6.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.
AcouSort AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr4.13B | 31.87 | 14.59% | 1.60% | -1.64% | -14.61% | |
56 Neutral | kr40.25M | 14.34 | 21.37% | ― | 837.37% | ― | |
52 Neutral | kr1.54B | -1.81 | -49.84% | ― | -15.45% | -164.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr62.56M | -0.51 | -279.07% | ― | 31.66% | 79.68% | |
44 Neutral | kr331.60M | -1.31 | -60.76% | ― | 79.55% | 90.21% | |
42 Neutral | kr52.91M | -4.71 | -76.74% | ― | 43.22% | 36.11% |
* Healthcare Sector Average
SE:ACOU
AcouSort AB
2.45
-0.70
-22.22%
SE:BICO
BICO Group AB Class B
21.55
0.27
1.27%
SE:CEVI
CellaVision AB
172.40
2.77
1.63%
SE:IMMNOV
Immunovia AB
0.09
-0.32
-78.86%
SE:QLINEA
Q-linea AB
17.35
-8.85
-33.79%
SE:FLUI
Fluicell AB
29.30
11.00
60.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.